Can Commercial Metals Sustain Its Strong Core EBITDA Growth Momentum?
CMC's core EBITDA surges y/y in the first nine months of fiscal 2026, aided by acquisitions, margin expansion and TAG Program benefits.
CMC - Commercial Metals Company
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$82.00
DETAILS
HIGH:
$89.00
LOW:
$75.00
MEDIAN:
$80.00
CONSENSUS:
$82.00
UPSIDE:
18.58%
Stock News
Here's Why Commercial Metals (CMC) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Commercial Metals (CMC) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
[url="]Celularity Inc.[/url] (Nasdaq: CELU) (âCelularityâ), a longevity-focused regenerative and cellular medicine company, and [url="]MuseCell InnovationsÂ
CMC Named to Newsweek's America's Greatest Companies 2026 List
IRVING, Texas, Aug. 27, 2026 /PRNewswire/ -- CMC (NYSE: CMC) today announced that it has been named to Newsweek's America's Greatest Companies 2026 list. The annual ranking, developed by Newsweek in partnership with Plant-A Insights Group, recognizes 650 U.S. companies based on financial leadership, innovation, performance as an employer and sustainability.
Commercial Metals Company: Working On Its Foundation
Commercial Metals Company is executing a strategy focused on higher-margin, less capital-intensive operations following $2.5 billion in transformative M&A. Commercial Metals targets $1.65–$1.80 billion core EBITDA and $11B revenue by 2029, aiming to nearly double free cash flow per share. Leverage remains in the low 2s as Commercial Metals prioritizes EBITDA growth and shareholder returns via increased buybacks over rapid debt reduction.
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological
Amundi Purchases 11,065 Shares of Commercial Metals Company $CMC
Amundi lifted its holdings in Commercial Metals Company (NYSE: CMC) by 118.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 20,443 shares of the basic materials company's stock after purchasing an additional 11,065 shares during the quarter. Amundi's holdings in Commercial
Commercial Metals Company (CMC) Analyst/Investor Day Transcript
Commercial Metals Company (CMC) Analyst/Investor Day Transcript
Commercial Metals Targets $1.8B EBITDA, Expands Construction Solutions Strategy
Commercial Metals NYSE: CMC used its 2026 Investor Day to outline a strategy centered on expanding its early-stage construction offerings, improving operating performance and generating higher cash flow and returns by fiscal 2029.
CMC Highlights Position as a Leading, Early-Stage Construction Solutions Provider and Unveils Long-Term Financial Targets at 2026 Investor Day
IRVING, Texas, Aug. 5, 2026 /PRNewswire/ -- CMC (NYSE: CMC) (the "Company") today will host its 2026 Investor Day in New York City, where members of the Company's leadership team will outline CMC's strategic vision, growth opportunities, capital allocation framework, and long-term financial targets. "Over the last several years, we have taken deliberate steps to transform CMC into an industry-leading provider of solutions across the early-stage construction ecosystem.
CMC Announces $600 Million Increase in Share Repurchase Program Authorization
IRVING, Texas, Aug. 5, 2026 /PRNewswire/ -- CMC (NYSE: CMC) (the "Company" or "CMC") today announced that its Board of Directors has authorized a $600.0 million increase in the Company's existing common stock repurchase program, bringing the total current capacity of the program to approximately $717.0 million. Approximately $733.0 million of the Company's common stock has been repurchased under the existing program since its authorization in October 2021.
Commercial Metals Company (NYSE:CMC) Given Consensus Rating of “Moderate Buy” by Brokerages
Commercial Metals Company (NYSE: CMC - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fifteen research firms that are presently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong
Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality
SEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointments of Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Supply Chain, and Gloria Cosgrove as Senior Vice President, Quality. Both executives bring decades of leadership across pharmaceutical manufacturing, supply chain, and quality.
Why Commercial Metals (CMC) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cincinnati Financial: The Equity Portfolio Saved Q2, But Commercial Lines Need Attention
Cincinnati Financial Corporation reported strong Q2 net income driven by $1.3B in pre-tax investment gains, primarily from its sizable equity portfolio. Operating EPS declined to $1.43 as catastrophe losses and weaker Commercial Lines underwriting offset rising recurring investment income. Commercial Lines produced a 104.1% Q2 combined ratio and remained unprofitable for H1, with deterioration extending beyond catastrophe losses.
California Public Employees Retirement System Grows Stake in Commercial Metals Company $CMC
California Public Employees Retirement System grew its stake in shares of Commercial Metals Company (NYSE: CMC) by 11.5% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 277,877 shares of the basic materials company's stock after acquiring an additional 28,693 shares
Here's Why Commercial Metals (CMC) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Commercial Metals CEO Peter Matt Buys $500,000 in Shares. What Does This Mean for Investors Now?
8,230 shares were purchased at $61.30 per share for a total value of $504,499 on July 10, 2026. The transaction increased the CEO's direct equity holdings by 5%.
Price Targets
Commercial Metals price target raised to $80 from $75 at Barclays
$80.00
(was $73.69)
Richard Garchitorena
·
Barclays
Commercial Metals price target raised to $85 from $77 at Goldman Sachs
$85.00
(was $75.52)
Nick Cash
·
Goldman Sachs
Commercial Metals upgraded to Outperform from Neutral at BNP Paribas
$75.00
(was $61.58)
Tristan Gresser
·
BNP Paribas
Commercial Metals price target lowered to $77 from $80 at BMO Capital
$77.00
(was $69.20)
Katja Jancic
·
BMO Capital
Commercial Metals price target raised to $80 from $77 at Wells Fargo
$80.00
(was $74.11)
Timna Tanners
·
Wells Fargo
Commercial Metals price target raised to $88 from $83 at Morgan Stanley
$88.00
(was $72.36)
Morgan Stanley
Commercial Metals Company (CMC) PT Raised to $83 at Morgan Stanley
$83.00
(was $76.98)
Carlos De Alba
·
Morgan Stanley
Commercial Metals initiated with an Equal Weight at Barclays
$75.00
(was $70.70)
Richard Garchitorena
·
Barclays
Commercial Metals upgraded to Buy from Neutral at UBS
$89.00
(was $70.33)
UBS
Commercial Metals price target lowered to $77 from $80 at Wells Fargo
$77.00
(was $58.28)
Wells Fargo
Commercial Metals price target raised to $85 from $68 at Morgan Stanley
$85.00
(was $70.61)
Morgan Stanley
Commercial Metals price target raised to $85 from $78 at Jefferies
$85.00
(was $71.32)
Jefferies
Commercial Metals Company (CMC) PT Raised to $84 at Goldman Sachs
$84.00
(was $70.55)
Mike Harris
·
Goldman Sachs
Commercial Metals upgraded to Buy from Hold at Jefferies
$78.00
(was $66.19)
Jefferies
Morgan Stanley Upgrades Commercial Metals Company (CMC) to Overweight
$68.00
(was $60.87)
Carlos De Alba
·
Morgan Stanley
Commercial Metals price target raised to $76 from $69 at Goldman Sachs
$76.00
(was $60.92)
Mike Harris
·
Goldman Sachs
Commercial Metals downgraded to Hold from Buy at Jefferies
$70.00
(was $62.05)
Christopher LaFemina
·
Jefferies
Commercial Metals price target raised to $64 from $61 at Wells Fargo
$64.00
(was $59.50)
Wells Fargo
Commercial Metals initiated with an Overweight at Wells Fargo
$61.00
(was $58.36)
Timna Tanners
·
Wells Fargo
Commercial Metals price target raised to $57.50 from $53 at Morgan Stanley
$57.50
(was $49.18)
Carlos De Alba
·
Morgan Stanley